SparingVision Raises €44.5m For Mutation-Agnostic Eye Gene Therapy

French Biotech Tackling Retinitis Pigmentosa

A long-term, patient-centric group of investors is backing SparingVision's bid to develop a gene therapy treatment for retinitis pigmentosa that could be effective regardless of mutation.

Eye
RP is one of the most common inherited retinal diseases • Source: Archive

French ocular disease specialist SparingVision has completed a €44.5m financing to help advance its gene therapy approach to tackling retinitis pigmentosa (RP), one of the most common inherited retinal diseases that affects two million patients worldwide.

The round was led by 4BIO Capital and the University of Pittsburgh Medical Center's UPMC Enterprises, and included France's Jeito...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip